Novel pyridine-based chalcone analogs and triple negative breast cancer: potential therapy & molecular pathways
Arij Fouzat Hassan, Ola J Hussein, Hadeel Kheraldine, Sumayyah Saeed, Maysaloun Merhi, Jericha Miles Mateo, Hamda Al-Thawadi, Feras Alali, Ala-Eddin Al-Moustafa, Ashraf Khalil, Abdelbary Elhissi · 2026
Read Novel pyridine-based chalcone analogs and triple negative breast cancer: potential therapy & molecular pathways by Arij Fouzat Hassan, Ola J Hussein, Hadeel Kheraldine, Sumayyah Saeed, Maysaloun Merhi, Jericha Miles Mateo, Hamda Al-Thawadi, Feras Alali, Ala-Eddin Al-Moustafa, Ashraf Khalil, Abdelbary Elhissi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13458508.txt.
Description
Arij Fouzat Hassan and colleagues test new pyridine chalcones against triple-negative breast cancer in a 2026 study. Triple-negative disease lacks hormone and HER2 targets, resists standard therapy and recurs often, so new scaffolds are urgently needed. Fourteen novel chalcone versions were screened on two such cell lines, with OH17 and OH25 advancing alongside a standard drug as control.
Both compounds cut cell life at tiny doses, triggered death-like shape, sub-G1 build-up and Annexin staining, raised pro-death BAX and lowered ERK1/2 signals, with OH17 also shifting EGFR. Spread and colony growth fell sharply. The pair emerge as distinct leads for lab-stage work, though animal safety and benefit must still be proven.
Catalog record
| CREATOR | Arij Fouzat Hassan, Ola J Hussein, Hadeel Kheraldine, Sumayyah Saeed, Maysaloun Merhi, Jericha Miles Mateo, Hamda Al-Thawadi, Feras Alali, Ala-Eddin Al-Moustafa, Ashraf Khalil, Abdelbary Elhissi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |